Erythromycin Ethylsuccinate Suspension
NDC Package 69238-1504-2
Package Information
Erythromycin Ethylsuccinate (erythromycin) suspension is to reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin ethylsuccinate for oral suspension and other antibacterial drugs, erythromycin ethylsuccinate for oral suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. This formulation utilizes a suspension delivery system. Marketed by Amneal Pharmaceuticals Ny Llc, this product is identified by NDC 69238-1504 and is authorized under FDA application ANDA211204.
Identification & Billing
- RxCUI: 686400 - erythromycin ethylsuccinate 200 MG in 5 mL Oral Suspension
- RxCUI: 686400 - erythromycin ethylsuccinate 40 MG/ML Oral Suspension
- RxCUI: 686400 - EES 40 MG/ML Oral Suspension
- RxCUI: 686400 - erythromycin ethylsuccinate 200 MG per 5 ML Oral Suspension
- RxCUI: 686418 - erythromycin ethylsuccinate 400 MG in 5 mL Oral Suspension
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 69238 - Amneal Pharmaceuticals Ny Llc
- 69238-1504 - Erythromycin Ethylsuccinate
- 69238-1504-2 - 100 mL in 1 BOTTLE
- 69238-1504 - Erythromycin Ethylsuccinate
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 69238-1504-2 identifies a specific commercial package of 100 ml in 1 bottle of Erythromycin Ethylsuccinate, a human prescription drug labeled by Amneal Pharmaceuticals Ny Llc. This suspension is formulated for oral use and contains erythromycin ethylsuccinate as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Amneal Pharmaceuticals Ny Llc on November 04, 2019. The current certification is valid through December 31, 2027.
How is this Amneal Pharmaceuticals Ny Llc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 69238150402. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. There are 100 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Package segment to maintain the 5-4-2 structure.